Managing Polypharmacy in the Elderly March 21, 2012

Barbara Farrell BScPhm, PharmD, FCSHP Pharmacist, Bruyère Geriatric Day Hospital



Bruyère pour des soins continus. Bruyère Is Continuing Care.

# Objectives

Participants will be able to:

•Describe the impact of polypharmacy on patients and the

health care system

•Find and use screening for inappropriate

 Identify common cascades

•Develop plans to medications safely





# Outline

- Polypharmacy in the elderly
  - Scope
  - Consequences
- Screening tools
- Prescribing cascades
- Strategies to reduce polypharmacy



# Context

- Bruyère Geriatric Day Hospital
  - Outpatient
  - Frail, elderly patients
  - Functional assessment, rehabilitation, interprofessional health care (Phm: 0.4 FTE)
  - Patients referred: cognitive changes, falls, pain, safety concerns, caregiver stress
  - Twice/week x 8-12 weeks
  - Patient-focussed care plan



# The problems we see in the GDH

- Prescribing cascades and webs
  - Multiple medications (e.g. 25 is not unusual)
  - Medications contributing to cognitive impairment, falls etc.
  - Many medications no longer indicated
- What else?
  - Patients and caregivers unclear about the purpose of medications and confused about how to take them
  - Some conditions undertreated




# Polypharmacy

- Increased number of medications (e.g.>5), or use of "inappropriate" choices, doses
- Associated with increasing age and comorbidities
- Scope (CIHI 2011)
  - 2002
    - 59% of seniors had claims for  $\geq$  5 drug classes
    - 20% had claims for  $\geq$  10
  - 2009
    - 63% of seniors had claims for  $\geq$  5 drug classes
    - 23% had claims for  $\geq$  10
    - 30% of those >85 had claims for  $\ge$  10
- At Bruyère GDH, average of 15 drugs/person



#### **Prescriptions dispensed:**

# Rx / yr





# Ontario data

- From 1997-2006 (Bajcar et al)
  - Ontario drug claims  $\uparrow$  214%
    - from 13,294,276 to 43,348,670
  - Population growth 65+ was 18.5%
  - Steepest: osteoporosis (2,347%), lipid-lowering (697%)
  - Symptom based medications ↓ (e.g. antibiotics, COPD, analgesics)
  - Claims per person (CPP) ↑ (e.g. cardiovascular from 3.25 to 9.48) as did number of unique classes
  - CPP increases with age and female sex



# Elderly are at increased risk

Due to:

- physiologic changes (increased sensitivity to benzodiazepines, analgesics, antihypertensives)
- reduced kidney and liver function (harder to excrete drugs)
- reduced body fat (changes distribution of drugs)
- existing conditions
  - dementia delirium
  - poor kidney function CHF
  - poor balance falls
  - reduced baroreceptor reflex orthostatic hypotension



# What is the impact?

- On people
  - decreased compliance, drug-drug interactions, errors and adverse drug reactions
  - 25% report ADR, 28% ameliorable and 11% preventable Gandhi et al
  - 23% report ADR after hospital discharge (72% due to medication) Forster et al
- On health care utilization
  - hospital admissions (preventable, drug-related)
- On cost (CIHI 2008; 6 provinces)
  - one billion from publicly funded programs
  - 17.4% of health care spending ( $\uparrow$ 15% in 10 years)



# Qualitative insights into polypharmacy

- Interviews with GPs (Anthierens et al)
  - Side effects not always recognized
  - Difficult to keep an overview of the exact medication intake (esp. with self medication, compliance)
  - Additional drugs are prescribed when it seems like previous doses didn't work
  - It's difficult to get people to stop medications
  - Feel pressured to prescribe according to guidelines though negative impact of polypharmacy may outweigh benefits
  - Other prescribers are involved (reluctant to change)



# Patient factors

- Patients may be reluctant to taper 'old favourites' e.g. benzodiazepines
- Tendency to view some medications as harmless multivitamins, Vitamin E, Asa, Gravol, NSAIDS – underreporting of use
- Compliance may be poor, leading to new drugs added
- Expectation that each issue will be addressed with a prescription
- Lifestyle recommendations are not valued as heavily e.g. exercise, non-medication pain management, insomnia



# Time constraints

- Some models of funding for MDs do not encourage medication reviews
- Time consuming to review all meds, and history behind each one
- Newly inherited patients can have complex histories
- Hospital to community GP large gap of communication re: medication changes
- New symptoms drug side effects vs disease process – this requires time to review



## Screening and assessment tools





# Screening criteria, processes

#### Beer's criteria

- http://www.americangeriatrics.org/health\_care\_professionals/ clinical\_practice/clinical\_guidelines\_recommendations/2012
- START and STOPP criteria
  - <u>http://www.biomedcentral.com/imedia/3973756062468072/</u> <u>supp1.doc</u>
- Medication assessment processes
  - "Medication Appropriateness Index", "NO TEARS" tool
  - "Pharmacotherapy Work Up" (indication, effectiveness, safety, compliance)
  - "Therapeutic Thought Process" (caused by drug therapy? causative drug needed? indication? best drug? why not working?)



# Using Beer's and STOPP/START

- Group 1
- •Read the case
- •Apply the <u>Beer's</u> criteria to identify medication problems

Group 2

- •Read the case
- •Apply the <u>STOPP/START</u> criteria to identify medication problems



# Mrs. A

- Widow living alone
- 84 years old
- Severe knee pain limiting mobility
- Often confused, unable to get out of bed
- Has had 3 falls in the last year
- Doesn't want to go out anymore
- Not always taking meds
- Children think she should no longer be living alone
- Medications found at home (\* = in dossette):

- ASA 81mg daily
- ibuprofen 400mg bid\*
- dimenhydrinate 50mg qhs
- Iorazepam 1mg qhs\*
- warfarin as directed\*
- metoprolol 50mg bid\*
- amlodipine 10mg daily\*
- ramipril 5mg daily\*
- Lakota capsules qid
- furosemide 40mg bid\*
- atorvastatin 40mg daily\*
- dextromethorphan syrup
- Iansoprazole 30mg daily\*
- Oxybutynin XL 10mg daily\*
- Vit. B12 1200mcg daily\*
- Slow-K daily\*
- Calcium/Vit D bid\*



## Impressions

- Were the criteria effective in identifying drugtherapy problems?
- Were there other problems not picked up by these screening tools?





- Frequently used to identify inappropriate prescribing
- List of medications
- Limitations:
  - Several drugs no longer available or rarely used
  - Recommend avoidance regardless of medical disease
  - Recommend avoidance based on presence of medical disease
  - Does not address underutilization



# STOPP/START

- More detailed
- Provides clinical context
- Divided into physiologic systems
- Limitations:
  - Lack evidence for reducing morbidity, mortality or cost
  - Don't account for many ER visits (e.g. insulin, warfarin)
  - Requires updating as guidelines change



# **Prescribing Cascades**





## What is a prescribing cascade?

An adverse drug reaction is interpreted as a new disease and a new medication is started

> An adverse drug reaction is interpreted as a new disease and another new medication is started

> > An adverse drug reaction is interpreted as a new disease and yet another new medication is started



## Common prescribing cascades

- Ibuprofen  $\rightarrow$  hypertension  $\rightarrow$  antihypertensive therapy
- Metoclopramide  $\rightarrow$  parkinsonism  $\rightarrow$  Sinemet
- Amlodipine  $\rightarrow$  edema  $\rightarrow$  furosemide
- Gabapentin  $\rightarrow$  edema  $\rightarrow$  furosemide
- Ciprofloxacin  $\rightarrow$  delirium  $\rightarrow$  risperidone
- Lithium  $\rightarrow$  tremor  $\rightarrow$  propanolol
- Buproprion  $\rightarrow$  insomnia  $\rightarrow$  mirtazepine
- Donepezil  $\rightarrow$  urinary incontinence  $\rightarrow$  oxytutynin
- Amiodarone  $\rightarrow$  tremor  $\rightarrow$  lithium
- Venlafaxine  $\rightarrow$  tremor  $\rightarrow$  diazepam



## Common prescribing cascades

- Meperidine  $\rightarrow$  delirium  $\rightarrow$  risperidone
- Beta-blocker  $\rightarrow$  depression  $\rightarrow$  antidepressant
- Amitriptyline  $\rightarrow$  decreased cognition  $\rightarrow$  donepezil
- Narcotic  $\rightarrow$  constipation  $\rightarrow$  senokot
- Senokot  $\rightarrow$  diarrhea  $\rightarrow$  imodium
- Lorazepam  $\rightarrow$  morning drowsiness  $\rightarrow$  caffeine
- Enalapril  $\rightarrow$  cough  $\rightarrow$  dextromethorphan
- Furosemide  $\rightarrow$  hypokalemia  $\rightarrow$  Slow K
- Omeprazole  $\rightarrow$  low B12  $\rightarrow$  B12 supplement



#### How did Mrs. A's prescribing cascade happen?



#### About 10 years ago


ago

Last 2 years

- Husband died; lorazepam
- Knee pain: Ibuprofen
- Hypertension; ramipril
- Cough; dextromethorphan
- Hypertension; amlodipine
- Daughter told her to take ASA for blood pressure
- Ankle swelling; furosemide
- Potassium low; potassium
- Nausea; dimenhydrinate
- Nausea (and taking ibuprofen): lansoprazole
- B12 levels low; B12 supplement
- Knee pain: Lakota
- Nocturia; oxybutynin
- Osteopenia: calcium/Vitamin D



## The prescribing web that resulted





## Strategies to reduce polypharmacy





## Strategies to reduce polypharmacy

- Calculate the pill burden
- Use screening criteria for 'inappropriate' medications
- Always consider a new symptom as possibly druginduced (review chronology of medications)
- Consider stopping/tapering medications
- Consider reducing dose with age
- Do a drug interaction check
- Review goals of care and treatment targets
- Prescribe strategically (e.g. reduce pill burden, simplify regimen, use meds for more than one purpose)



#### Rocking the boat – stopping medications

- Medications can be stopped without causing harm
  - Garfinkel successful discontinuation in 81%
- But, symptoms or withdrawal reactions can happen
- Get started with medication where there is:
  - Risk of harm with no known benefit
  - Little chance ADWE
  - Unclear or no indication
  - Indication but unknown or minimal benefit
  - Benefit but side effect or safety issues



# Getting buy in

- Start a medication review with questions like:
  - What questions do you have about your medications?
  - What medications do you feel most strongly about keeping?
  - What medications do you wonder about how well they're working for you?
- Find out:
  - How long? What does the drug do? How do they take it? Have they had any problems with it?
- Try to go one at a time
  - Involve the patient in choosing and monitoring



#### Adverse drug withdrawal events (ADWE)

- "A clinically significant set of symptoms or signs caused by the removal of a drug"
- Can be:
  - Physiological withdrawal reaction tachycardia (betablocker); rebound hyperacidity (PPI)
  - Symptoms of the underlying condition arthritis pain after stopping an NSAID
  - New symptoms excessive sweating with stopping SSRI
- Increased risk with:
  - Longer duration, higher doses, short half-life
  - History of dependence/abuse
  - Lack of patient 'buy-in' (may feel abandoned)



# Drugs that often have ADWEs

DRUG	MONITORING	DRUG	MONITORING
ß-Blockers	↑ HR, ↑ BP, angina	NSAIDs	↑ pain, ↑ PRN use, mobility changes
Diuretics -furosemide -HCTZ	↑ pedal edema, chest sounds, SOBOE, ↑		
	weight	Amlodipine	↑ BP
Hypnotics -lorazepam -zopiclone	poor sleep, ↑ anxiety, agitation, tremor	Gabapentin (for pain)	↑ pain, ↑ PRN use, mobility changes
PPIs, Domperidone	Rebound heartburn, indigestion	Digoxin	palpitations, ↑ HR
Narcotics	<ul> <li>↑ pain, ↑ PRN</li> <li>use, mobility</li> <li>changes, insomnia,</li> <li>anxiety, diarrhea</li> </ul>	Anti convulsants	anxiety depression seizures



# Drugs that often have ADWEs

DRUG	MONITORING	DRUG	MONITORING
Anti- depressants -citalopram -venlafaxine -mirtazapine -amitriptyline	Early: -chills, malaise -sweating -irritability -insomnia -headache <u>Late:</u> -depression recurrence	Baclofen Anti-psychotics	agitation, confusion, nightmares, ↑ spasms or rigidity -insomnia
Nitro Patch Steroids	angina, ↑ BPanorexia, ↓ BP,nausea, weakness,↓ blood sugars		-restlessness -hallucinations -nausea



# Drugs that rarely have ADWEs

- colace
- iron
- calcium
- vitamins (E, B12, multiple vitamins, folic acid....)
- bisphosphonates
- fibrates
- glucosamine



## Steps to consider

- Know when to stop and when to taper slowly
- Involve the patient in the decision (consider incentives)
- Offer safer alternative therapies
- Get the patient/family involved in the monitoring
- Involve team members (nurse, pharmacist, dietician, social worker, physiotherapist, occupational therapist etc.)
- Include non-pharmacological approaches (sleep hygiene, recreational services)
- Provide reinforcement




## Steps to consider

- Be up front about the need to withdraw slowly and monitor for ADWE, as well as how long ADWE can last
- Keep the message clear & say it often
- Follow up and document the progress
- Make several attempts at withdrawal
- Use a variety of educational media
  - Verbal
  - Written handouts
  - Medication Logs to organize all the information
- Empower patients to avoid future problems




#### Mrs. A's medication changes






#### Mrs. A's medication changes





#### Mrs. A's medication changes





## After a 10 week Day Hospital stay:

#### Mrs. A's medications

- Hydromorphone 0.5mg q12h
- Hydrochlorothiazide
   12.5mg daily
- Bisoprolol 2.5mg daily
- Warfarin as directed
- Caltrate Select with
   Vitamin D twice daily
- Lactulose 15ml daily

Mrs. A's life:

- Knee pain much improved
- Getting out of the house now
- Urgency and nocturia better (up 1-2x/night)
- Sleep improved (to bed 10pm, up about 7am)
- Meal times normal (8, noon, 6)
- Bruising and gum bleeding gone
- No heartburn, nausea, cough or swollen ankles



# Strategic prescribing for Mrs. A

- Reduce pill burden
  - Medication assessment for continued indication, effectiveness, safety, compliance
- Simplify regimen
  - Combine when possible
  - Reduce medication-taking frequency
- Mrs. A's results
  - From 17 to 7 medications
  - From 27 to 8 pills/doses per day
  - Now twice daily



# Adapting guidelines for the frail elderly

#### Hypertension

- <80: 140/90 (CHEP)
- >80: 150/80
- Caution if renal dysfunction, CHF, other comorbidities
- Avoid diastolic <60 (65 if CAD)
- Avoid systolic <120</li>
- >80: 120/60 to 150/80

#### Diabetes

 Choose targets to avoid hypoglycemia

If frail

- HgA1C about 8%? Or 8.5%?
- FBS < 10?
- 2 hour post meal < 14?



### Adapting goals at the end-of-life

- Look at the remaining life expectancy and consider time until benefit
- Establish the goals of care and treatment targets
- Focus on symptomatic treatment
- Dial down the preventative treatment
- Weigh the pros and cons of treatment



# Conclusion

- Decreasing medication use in the elderly can:
  - Reduce adverse events (e.g. falls, hospitalizations)
  - Reduce pill burden and costs
  - Increase adherence with remaining medications
  - Improve quality of life
- All team members have a role to play in the success of the tapering process
- Taking the first step and developing a plan for medication review and strategic prescribing are key
  - Choose a patient
  - Choose a drug



# Tips for working with a pharmacist

- Meet with local community pharmacists
- Develop a plan to help a patient reduce medication use who will do what?
- Figure out how to get paid
  - Pharmacist (e.g. MedsCheck, MedsCheck follow-up, MedsCheck at home)
  - Family physician (e.g. medication review code, CHF annual review, diabetes quarterly reviews, case coordination?)



- Chapter 3: Primary health care and prescription drugs key components to keeping seniors healthy. In: Health Care in Canada, 2011: A Focus on Seniors and Aging. Canadian Institute for Health Information: Dec, 2011.
- Ramage-Morin P. Medication use among senior Canadians. Statistics Canada. Health Reports, Vol 20, No. 1, March 2009.
- Bajcar JM, Wang L, Moineddin R, Nie JX, Tracy CS, Upshur RE. From pharmaco-therapy to pharmaco-prevention: trends in prescribing to older adults in Ontario, Canada, 1997-2006. BMC Fam Pract 2010;11:75.
- Hajjar ER et al., Polypharmacy in Elderly Patients. Am J Geriatr Pharmacother 2007; 5: 345-51



- Forster et al. Adverse events among medical patients after discharge from hospital. CMAJ 2004:170:345.
- Anthierens et al. Qualitative insights into general practitioners' views on polypharmacy. BMC Family Practice 2010;11:65
- Hamilton, H et al. Inappropriate prescribing and adverse drug events in older people. BMC Geriatrics 2009;9:5.
- Boparai M. et al., Prescribing for older adults. Mt Sinai J Med 2011; 78: 613-26
- Levy et al. Beyond the Beers criteria: a comparative overview of explicit criteria. Ann Pharm 2010:44;1968-75.
- Steinman MA et al., Beyond the prescription: medication monitoring and adverse drug events in older adults. J Am Geriatr Soc 2011; 59: 1513-20



- Steinman MA et al., Managing medications in clinically complex elders. JAMA 2010; 304(14): 1592-1601
- Farrell B et al. Drug-related problems in the frail elderly. Can Fam Phys 2011;57:168-169.
- Tamblyn R et al. Do too many cooks spoil the broth? Multiple physician involvement in medical management of patients and potentially inappropriate drug combinations. CMAJ1996;154(8):1177-1184.
- Frank C. Conscientious family physicians and polypharmacy. Can Fam Phys 2002;48:1430-3.
- FrankC What drugs are our frail elderly patients taking? Can Fam Phys 2001;47:1198-1204.
- Chen L et al. Discontinuing benzodiazepine therapy: An interdisciplinary approach at a geriatric day hospital. Can Pharm Journal 2010;143:286-295.



- Gandhi et al. Adverse drug events in ambulatory care. NEJM 2003;348:1556
- Farrell B et al. Stopping medications in complex continuing care: the example of baclofen and dantrolene. CJHP 2006;59:264-72.
- Farrell B et al. Facilitating the process of medication reevaluation and withdrawal in the long-term institutionalized population: the example of cisapride. CJHP 2003;56:32-41.
- Shoba I et al. Medication Withdrawal Trials in People Aged 65 Years and Older: A Systematic Review. Drugs Aging 2008;25(12):1021–1031
- Sergi G et al. Polypharmacy in the elderly: can comprehensive geriatric assessment reduce inappropriate medication use? Drugs Aging 2011;28(7):509-518.



- Holland et al. Medication review for older adults. Geriatrics and Aging 2006;9:203-208.
- O'Mahony D et al. Pharmacotherapy at the end-of-life. Age and Ageing 2011;40:419-422.
- Commentary. Reconsidering medication appropriateness for patients late in life. Arch Intern Med 2006;166:605-609.
- Graves T et al. Adverse events after discontinuing medications in elderly outpatients. Arch Intern Med 1997;157:2205-2210.
- Culberson JW et. al. Prescription drug misuse and abuse in the elderly. Geriatrics 2008;63(9):22-26,31.
- Bain et al. Discontinuing medications: a novel approach for revising the prescribing stage of the medication-use process. JAGS 2008;56:1946.



- Kaur et al. Interventions that can reduce inappropriate prescribing in the elderly. A systematic review. Drugs and Aging 2009;26(12):1013-1028.
- Garfinkel et al. Feasibility study of a systematic approach for discontinuation of multiple medications in older adults. Arch Intern Med 2010;170:1648-1654.
- Dore N et al. Intentional medication nonadherence in a geriatric day hospital. CPJ 2011;144(6): 260-264.

